Biopharma M&A in 2024 — Five Considerations for Deal Execution
Vantage Partners
JANUARY 19, 2024
Activity among Big Pharmas in 2023 ( Merck + Prometheus ; Pfizer + Seagen ) dominated headlines, and major deal announcements around this year's JPM Healthcare conference (including Merck's acquisition of Harpoon Therapeutics , J&J's acquisition of Ambrx , and GSK's acquisition of Aiolos Bio ) present signals that this trend will only continue (..)
Let's personalize your content